OPKO Health, Inc. (NASDAQ:OPK) Stock Rated “Hold” by Wall Street Brokerages

OPKO Health, Inc. (NASDAQ:OPK) has been given a consensus recommendation of “Hold” by the six ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $1.55.

Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating on shares of OPKO Health in a research note on Wednesday, July 29th. Weiss Ratings reissued a “sell (d-)” rating on shares of OPKO Health in a report on Thursday, August 13th. Finally, Zacks Research upgraded shares of OPKO Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, September 28th.

OPKO Health Trading Up 0.7%

NASDAQ OPK opened at $1.38 on Friday. The stock has a 50-day simple moving average of $1.51 and a 200 day simple moving average of $1.36. The company has a market capitalization of $1.03 billion, a PE ratio of -15.33 and a beta of 1.51. The company has a current ratio of 3.35, a quick ratio of 2.93 and a debt-to-equity ratio of 0.28. OPKO Health has a 12 month low of $0.98 and a 12 month high of $1.75.

OPKO Health (NASDAQ:OPK) last released its earnings results on Monday, July 27th. The biotechnology company reported ($0.01) earnings per share for the quarter, beating the consensus estimate of ($0.08) by $0.07. The firm had revenue of $163.58 million for the quarter, compared to analyst estimates of $131.23 million. OPKO Health had a negative return on equity of 5.88% and a negative net margin of 12.40%. The company’s quarterly revenue was up 4.3% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.19) earnings per share. Research analysts forecast that OPKO Health will post -0.23 EPS for the current year.

Hedge Funds Weigh In On OPKO Health

Several institutional investors have recently modified their holdings of OPK. Two Sigma Securities LLC bought a new stake in shares of OPKO Health during the second quarter worth $27,000. World Investment Advisors boosted its stake in OPKO Health by 63.8% in the 4th quarter. World Investment Advisors now owns 66,520 shares of the biotechnology company’s stock worth $84,000 after purchasing an additional 25,902 shares during the period. Apella Capital LLC acquired a new position in OPKO Health in the 1st quarter worth $34,000. EP Wealth Advisors LLC bought a new position in OPKO Health during the 2nd quarter worth about $45,000. Finally, Diversify Advisory Services LLC bought a new position in OPKO Health during the 2nd quarter worth about $37,000. Institutional investors own 64.63% of the company’s stock.

About OPKO Health

OPKO Health, Inc is a healthcare company focused on diagnostics and pharmaceuticals. Through its diagnostics businesses, the company provides laboratory services and specialized tests intended to support the detection, diagnosis and management of disease. Its operations include BioReference Health, a clinical laboratory business serving physicians, hospitals, employers and patients, as well as the 4Kscore test, which helps assess the risk of aggressive prostate cancer.

OPKO’s pharmaceutical business develops and commercializes treatments for conditions including kidney disease, endocrine disorders and growth-related conditions.